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Abstract
Background: Autism is a neurodevelopmental disorder characterized by impairments in social behavior, communication
difficulties and the occurrence of repetitive or stereotyped behaviors. There has been substantial evidence for dysregulation
of the immune system in autism.
Methods: We evaluated differences in the number and phenotype of circulating blood cells in young children with autism
(n = 70) compared with age-matched controls (n = 35). Children with a confirmed diagnosis of autism (4–6 years of age)
were further subdivided into low (IQ,68, n = 35) or high functioning (IQ$68, n = 35) groups. Age- and gender-matched
typically developing children constituted the control group. Six hundred and forty four primary and secondary variables,
including cell counts and the abundance of cell surface antigens, were assessed using microvolume laser scanning
cytometry.
Results: There were multiple differences in immune cell populations between the autism and control groups. The absolute
number of B cells per volume of blood was over 20% higher for children with autism and the absolute number of NK cells
was about 40% higher. Neither of these variables showed significant difference between the low and high functioning
autism groups. While the absolute number of T cells was not different across groups, a number of cellular activation
markers, including HLA-DR and CD26 on T cells, and CD38 on B cells, were significantly higher in the autism group
compared to controls.
Conclusions: These results support previous findings that immune dysfunction may occur in some children with autism.
Further evaluation of the nature of the dysfunction and how it may play a role in the etiology of autism or in facets of
autism neuropathology and/or behavior are needed.
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Introduction
Autism is a lifelong neurodevelopmental disorder characterized
by social deficits, impaired verbal and nonverbal communication
and the presence of stereotyped behaviors or circumscribed
interests [1]. Autism, together with Asperger syndrome and
pervasive developmental disorder not otherwise specified, referred
to as autism spectrum disorders (ASD), form a spectrum of
conditions with varying degrees of impairment that are classified as
pervasive developmental disorders in the DSM-IV [2]. The
current estimate of prevalence is approximately 1:110 [3], which is
substantially higher than earlier estimates [4]. Numerous attempts
at determining susceptibility genes through a number of large
consortia have indicated that multiple genes, including immune
related genes, may be associated with autism. Interestingly, none
of the defined mutations, genetic syndromes and de novo copy
number variations account for more than 1–2% of cases of autism
[5].
There has been substantial speculation about the etiology(ies) of
ASD, but for the vast majority of cases, the cause remains
unknown. It has become clear that there will be many causes of
autism that will likely have varying contributions from genetic and
environmental factors. One persistent suggestion has been that an
immune dysfunction may contribute to certain forms of autism.
There have been numerous findings of altered immune function in
autism [6]. As long as 45 years ago, Stubbs [7] noted that children
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with autism had altered responses to T cell mitogens, such as
phytohemagglutinin or pokeweed antigen and these findings have
been replicated in subsequent studies [8–10]. More definitive
studies have since highlighted the presence of inflammation in the
brain and the activation of microglia [11] as well as evidence for
altered peripheral immune function in autism, including increased
cytokine levels in the plasma such as interleukin (IL)-1b, IL-6, and
IL-8 [12], elevated levels of complement proteins [13], decreased
cellular activity of NK cells [14–16], increased monocyte
activation [17,18], and a reduced number of CD4+ T cells
[10,19,20]. Pliopys et al. [21] reported that a substantial number
of individuals with autism demonstrated an increased number of
HLA-DR+ T cells and this finding has been confirmed by Warren
et al. [22]. In addition, a number of studies have reported
abnormal antibody responses to brain and CNS proteins [23,24].
Skewed immunoglobulin (Ig) responses, such as decreased total
serum IgG levels but increased isotype IgG4, have also been
reported in autism [25–27].
Taken together, these data are suggestive of a link between
autism and immune dysfunction and that specific cellular
phenotypes or activation status of immune cells may be altered
in autism. Autism is also associated with a variety of co-existing
symptoms including seizures, sleep disturbances and gastrointes-
tinal problems [28] many of which may be influenced by altered
immune function. However, the data are often clouded by
methodological concerns. The often heterogeneous populations
of subjects analyzed, the use of siblings as controls and the
disparate age ranges between controls and cases have led reviewers
of this literature to be very cautious in drawing conclusions.
Krause et al. [29] conclude that ‘‘Although various immune
system abnormalities, involving both cellular and humoral aspects
of the immune system, have been reported in children with autistic
disorder, previous studies are largely association based, and, it
remains difficult to draw conclusions regarding the role of immune
factors in the etiopathogenesis of this neurodevelopmental
disorder.’’
The current study was designed to search for cellular markers of
autism. Participants were selected from a very narrow age range (4
to 6 years) of children, to coincide with peak symptom
presentation and to ensure a stable diagnosis. In addition,
participants were only enrolled in the diagnostic group if they
had a confirmed diagnosis of strictly defined autistic disorder
(N = 70). Similarly, an age and gender matched control group of
typically developing children (N = 35) was comprehensively
evaluated to avoid inclusion of individuals with an autism
spectrum or other neurodevelopmental disorder. The aim of the
investigation was to evaluate changes in the frequency of distinct
cellular phenotypes in autism with the goal of identifying immune-
specific differences that could be further investigated for a
potential role as biomarkers. A number of parameters of immune
system status including cell number, cell ratios and cell surface
antigen intensities were assessed using microvolume laser scanning
cytometry.
Methods
Participants
The experimental subjects were recruited from the UC Davis
M.I.N.D. Institute Clinic and community support groups such as
Families for Early Autism Treatment (FEAT), Regional Centers,
referrals from clinicians, and area school districts. Parents of
children who met the diagnostic criteria were provided with an
information sheet containing a description of the study and contact
information. Typically developing subjects were recruited from
area school districts and community centers. Informed written
consent was obtained from parents prior to any assessments or
procedures. The study was explained in simple language to the
children and verbal assent was obtained from higher functioning
children who were capable of understanding the study process. All
participants were assigned a numerical code to maintain
anonymity of the children and their test results. The subject
number served as the primary identifier on research data forms.
Following informed consent, interested subjects completed the
diagnostic and psychological measures. All facets of the study were
approved by the University of California Davis Institutional
Review Board (IRB). For the duration of the study, there were no
adverse events.
The inclusion criteria for the three groups consisted of the
following. The children in the autism diagnostic group required a
diagnosis of Autistic Disorder based on the DSM-IV criteria [2].
Children with pervasive developmental disorder-not otherwise
specified (PDD-NOS) or Asperger Syndrome were excluded from
the study. The diagnosis of Autistic Disorder was corroborated by:
1) the Autism Diagnostic Observation Schedule-Generic (ADOS-
G; [30], 2) Autism Diagnostic Interview-Research (ADI-R;
[31,32], and 3) clinical judgment by one of the authors (BAC).
The ADOS-G was used to assess children with autism to confirm
diagnosis for inclusion in the study and is comprised of four
different modules that are administered based on the language
ability of the child. The ADOS provides an algorithm with cut-offs
for autism and autism spectrum disorders [33]. The Autism
Diagnostic Interview-Revised (ADI-R; [31] was administered to
the parents of children with suspected autism. The ADI-R
generates a diagnostic algorithm based on the DSM-IV [2]
criteria for Autistic Disorder. The autism diagnostic group was
further divided based on the level of intellectual functioning as
follows: High functioning autism (HFA) having an IQ$68 and
low-functioning autism (LFA) having an IQ,68. The typically
developing children (TYP) had intellectual functioning within the
average to above average range with a minimum IQ$68.
Typically developing control children were assessed using the
Social Communication Questionnaire (SCQ; [34], a valuable
screening tool that was completed by parents to ensure the absence
of symptoms of autism. Children who had scores above the cutoff
were excluded from the typically developing group, and were
referred for further diagnostic evaluation (N = 1). In addition, all
children were assessed using the Stanford-Binet Intelligence Scale-
Fourth Edition [SB4; 35], a standardized measure of cognitive
functioning for children between 2 and 18 years, which is divided
into several parts, including Verbal Reasoning, Abstract/Visual
Reasoning, Quantitative Reasoning, and Short-term Memory.
The SB4 was used to obtain a measure of overall IQ for inclusion
into the study as well as for the assignment to high ($68) and low
(,68) functioning autism groups. Similarly, all children underwent
assessment with the Vineland Adaptive Behavior Scales-Interview
Edition (VABS; [36], a structured parent interview format
designed to assess a child’s ability to perform daily activities
required for personal and social sufficiency; this was administered
to obtain a measure of adaptive functioning across all participants.
As a further assessment, the AGRE Medical History Forms were
given to the parents of all subjects to provide a comprehensive
medical history. The interview requires the parent to provide
demographic, medical and family history information.
The exclusion criteria for all subjects consisted of the presence
of Fragile X or other serious neurological (e.g., seizures),
psychiatric (e.g., bipolar disorder) or known medical conditions
including autoimmune disease and inflammatory bowel diseases/
celiac disease. All subjects were screened via parental interview for
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current and past physical illness. Children with known endocrine,
cardiovascular, pulmonary, liver or kidney disease were excluded
from enrollment in the study.
A total of 136 children between 4-years, 0-months and 6-years,
11-months were enrolled in this investigation. Twenty-one
children were excluded due to failure to meet inclusion criteria
or noncompliance with the majority of the protocol. The final
sample consisted of 105 children who were selected to balance age
and gender across experimental groups. Demographic information
for the 105 subjects is presented in Table 1 including gender, age,
IQ and ethnicity across the groups.
Participation in the study required two visits. Child assessments
and parental interviews were conducted at the UC Davis M.I.N.D.
Institute Research Clinic on the first visit; testing lasted for
approximately 3 1/2 contact hours. The parents were sent letters
providing the results of their child’s performance. The second visit
consisted of a blood draw completed by a pediatric phlebotomist
and research staff via standardized procedures (see below).
Sample Collection Procedures
For each child, approximately 5 ml of blood was drawn by one
of two clinical phlebotomists into Vacutainer tubes containing
EDTA (BD Biosciences, San Jose, CA). Immediately following
collection, the tube was gently inverted 8 to 10 times to mix the
anticoagulant with the blood. The tube was then wrapped in
parafilm and bubble wrap and placed in a biohazard bag between
coolant packs in a Styrofoam transport container. The blood
draws were taken within one week of the diagnostic and
psychological assessments for each of the children. All blood
draws were conducted in the early morning hours between 8:00
am and 10:00 am following an overnight fast (no consumption of
food or drink other than water after midnight). Topical anesthetics
were not employed to prevent contamination of the sample. If the
participant was ill (presented with a cold, fever or other common
illness), the blood draw was not taken until the child’s health status
was stable/recovered for 48 hours. The samples were sent via
Courier to PPD Biomarker Discovery Sciences (Menlo Park, CA,
USA, formerly known as SurroMed, Inc.) arriving in the lab
within six hours of the blood draw. Cytometric analyses of the
blood samples were carried out immediately on receipt of the
samples in the lab. PPD personnel were blind to the diagnosis until
after all samples were assayed and a report of preliminary findings
was presented.
Analytic Methods
The protocol for immune phenotyping included 64 three-color
cellular assays performed by microvolume laser scanning cytom-
etry on the SurroScanTM system [37–39]. The assays are well-
suited for evaluating cellular immune markers. Monoclonal
antigen-specific antibodies were purchased from various commer-
cial vendors and developed into PPD assays. Three different
fluorophores, Cy5, Cy5.5 [40,41] and the tandem dye Cy7-APC
[42,43], were coupled to individual monoclonal antibodies specific
for different cellular antigens in each assay. Each fluorophore was
measured in a separate detection channel. Aliquots of whole blood
were added to 96-well micro-titer plates containing the appropri-
ate antibody-dye combinations for each assay, incubated in the
dark at room temperature for 20 minutes, diluted with an
appropriate buffer and loaded into Flex32TM capillary arrays
(PPD) and analyzed with SurroScanTM. Images were converted to
a list-mode data format with in-house software [44]. Fluorescence
intensities were compensated for spectral overlap of the dyes so
values are proportional to cell surface antigen density. Standard
beads were run with every sample and were used to monitor
systematic instrument errors.
Prior to this study, PPD developed and established quality and
baseline measures with twenty blood bank samples for the 64
different three-reagent cellular assays used in this study. Standard
template gates were established using these results plus additional
staining controls for all individual reagent and dye combinations.
Template gates were established using FlowJoTM cytometry
analysis software (Tree Star, Inc., Ashland, OR) customized for
PPD to enable upload of gates to an Oracle database. Gating
information was stored in the database and applied to the scan
data for each assay using SurroGateTM database-driven cytometry
analysis software in order to generate the resulting cell count and
antigen intensity data.
The assay panel allows the enumeration of major cell
populations: granulocytes, eosinophils, monocytes, CD4 and
CD8 T cells, B cells and NK cells. In addition, the assays allow
for finer phenotyping of cell subtypes based on the expression of
specific cell surface markers of activation, adhesion molecules,
receptors, etc. The assays monitor cell counts of more than 200
different cell populations, plus the relative levels of the different
cell surface antigens on specific populations. Template gates were
used to enumerate the cell populations of interest in all of the
assays. Invalid assays and those that do not support the template
gates were flagged. An analyst visually reviewed all assay results
prior to data upload. In this study, 105 subject samples were
analyzed with 64 assays for a total 6720 assays. Among the assays,
only 0.67% were invalid due to technical difficulties and have been
excluded from the analysis. An additional 4.8% required non-
standard gates due to slight inter-individual differences. These
results are used in the statistical analysis. Cell counts were
generally not affected but cell surface expression results may have
a larger but not statistically significant variation due to the
inclusion of these data.
Table 1. Demographic Variables for the three groups of
subjects evaluated in this study.
Characteristic HFA LFA TYPICAL
N 35 35 35
Male:Female Ratio 29:6 29:6 29:6
Age (Median) 5.2 5.5 5.7
IQ 79 56 115
Caucasian 23 21 30
Hispanic 5 6 0
Asian 3 2 2
African-American 0 1 1
Other 4 5 2
ADOS total (mean 6 SD) 13.362.2 15.962.4 -
ADOS communication (mean 6 SD) 5.561 5.861.4 -
ADOS social (mean 6 SD) 7.861.8 1061.9 -
ADOS play (mean 6 SD) 1.361.2 3.361.1 -
ADOS repetitive (mean 6 SD) 2.361.1 3.861.1 -
ADI social (mean 6 SD) 18.366.7 24.963.2 -
ADI verbal (mean 6 SD) 14.564.7 16.462.9 -
ADI nonverbal (mean 6 SD) 7.864.9 12.961.5 -
ADI repetitive behavior (mean 6 SD) 6.862.8 5.861.7 -
ADI Abnormal behavior (mean 6 SD) 4.160.9 4.760.5 -
doi:10.1371/journal.pone.0019299.t001
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Statistical Analyses
Statistical analyses were conducted to assess differences in cell
populations, 1) between the combined autistic group (HFA+LFA)
and the control group, 2) between each of the autism subgroups
and 3) among the three groups. With regard to two-group
comparison statistics, we applied to all data a univariate mean
comparison test that was either parametric or non-parametric
depending on the normality of the data. If the data were
approximately normally distributed, then parametric statistics
were used (t-test); if not, the nonparametric rank test (Wilcoxon or
Kruskal-Wallis test) was applied. All tests of hypotheses were two-
sided. Goodness-of-fit statistics (Shapiro-Wilk) and tests of
skewness and kurtosis were performed to assess normality.
Three-group comparisons were performed by ANOVA. The data
set for this study is broad, i.e., there are many more variables than
subjects. Consequently, many multivariate statistics such as
multivariate analysis of variance, which require more subjects
than variables, could not be conducted. This study was
underpowered for the number of variables being studied and
some interesting results would be overlooked if the univariate
statistics were ignored. Although the groups were carefully
controlled and matched for sex and ethnicity, the study is
underpowered to find differences based on sex and ethnicity.
Unadjusted P values are presented since this study is preliminary
and is the first to begin to explore cellular markers on different
blood cells. Moreover, the use of correction for multiple
comparisons in this area is debated [45]. Our hypothesis tests
included 644 variables from cell counts and cell surface marker
intensities. Multiple measures of the same cell population (e.g.
CD4 T cells) were combined into a single average for the analysis.
Differences at the univariate p-value,0.05 or lower, warrant
further consideration.
Results
There were multiple significant differences observed in immune
cell numbers and the surface expression of markers on immune
cells in children with autism compared with age and gender-
matched typically developing controls. For example, at the
p,0.05 level there were 151 variables where either cell count or
the intensity of cell surface markers were different between
children with autism and controls (Table 2).
In general, more differences were observed between children
with autism and typically developing controls than between the
low functioning (LFA) and high functioning (HFA) autism groups
based on IQ, although 33 variables were different between HFA
and LFA at the p,0.05 level. A summary of the significant
measures for each of the comparisons is shown in Table 2. For
each statistical level (p-value) the number of false-positive variables
expected to appear by chance (assuming all are independent) is
given in the first column. The significant differences between
autism and controls included both differences in cell counts and,
separately, differences in the intensity of cell surface marker
expression. Tables 3 and 4 represent variables that were
significantly different for cell counts and cell surface expression
markers intensities, respectively.
Analysis of immune cell counts
Cell count data were available for the major immune cell
populations i.e., neutrophils, lymphocytes, eosinophils, monocytes
and platelets. We found that the absolute numbers (cells per
microliter) of B cells and NK cells in children with autism were
significantly higher than counts from typically developing controls.
Although there were higher mean absolute numbers of total white
blood cells (WBC), neutrophils, T cells, the CD4 and CD8 T cell
subpopulations, monocytes, eosinophils and platelets in children
with autism, these differences in cell counts did not reach statistical
significance (Table 5).
Analysis of B cells
Absolute numbers of B cells were 20 to 25% higher in the
autism groups compared with the typically developing controls.
The B cell value represents an average based on nine separate B
cell assays that use CD20 as the B cell identifier. No differences
were seen within the autism group when comparing HFA with
LFA. B cell counts were significantly higher for both LFA
(p = 0.009) and HFA (p = 0.011) after adjustment for multiple
comparison compared with typically developing controls (Figure 1).
In addition, there were significant differences in activated B cell
subsets, including statistically significant increases in B cells that
expressed the activation marker CD38 in autism compared with
controls (394.76119.9 vs. 479.76210.2, p = 0.0081, Table 6). The
difference in CD38 positive (CD38p) B cell number in autism
tracked with the increase in total B cell population. CD38 negative
(CD38n) cell numbers were also higher but to a lesser extent
(164.5699.3 vs. 193.4684.6, p = 0.013). There were also increases
in mature B cell numbers as denoted by the absence of CD5
staining (CD5n) on B cells in autism subjects compared with
typically developing controls (Table 6, p = 0.0001). Notably,
although the number of B cells was increased in autism, the
number of immature B cells, as denoted by positive CD5 staining,
was not different between autism and controls (278.36142.1 vs.
329.46171.8, p = 0.14). These data suggest that B cells are
increased in autism and it is preferentially the activated and
mature phenotype which differs from controls.
Analysis of NK cells
Absolute numbers for NK cells were approximately 40% higher
in children with autism compared with controls (Table 5). The
measure of NK cells was based on an average of two separate NK
cell assays that use the markers CD56 and CD3, so that NK cells
Table 2. Significantly different immunophenotyping measures (including both cell counts and fluorescence intensities) between
study groups.
P value criteria Chance
Autism vs. Typically
developing
HFA vs. Typically
developing
LFA vs. Typically
developing HFA vs LFA
HFA vs. LFA vs. Typically
developing
p,0.001 ,1 21 3 22 1 12
p,0.01 6 77 25 76 7 54
p,0.05 32 151 101 162 33 139
Based on 644 variables.
doi:10.1371/journal.pone.0019299.t002
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are identified as CD56pCD3n. The difference in NK cell numbers
was significant for both HFA vs. controls (p = 0.037) and LFA vs
controls (p = 0.023), but no differences were observed between
HFA and LFA (Figure 2).
Analysis of cell surface marker intensities
As indicated in Table 4, there were many significant differences
in the intensity of cell surface markers expressed on immune cells.
At the p,0.05 level, there were 108 different variables denoting
intensities that were different between children with autism and
controls (Table 4). To help organize the data that are based on cell
surface marker intensities, we reviewed the top 20 intensity
variables with differences greater than 15% between the autism
and control groups and had adjusted p-values,0.05. These
variables are listed in Table 7. It is important to note that a
number of these variables represent cell surface markers that are
only present on rare cells for which the observed cell counts were
very low.
Of interest, HLA-DR, a marker of cellular activation, was
higher on CD8 T cells and CD4 T cells in the autism group
compared with typically developing controls. The T cell marker
CD26/dipeptidyl peptidase IV, which is associated with an
effector cell phenotype and is markedly elevated in human CNS
disorders such as multiple sclerosis, was increased on CD8 T cells
in autism compared with controls. Another noteworthy finding
was that CD95 expression was increased on CD14 expressing
monocytes compared with controls. The marker CD95 is often
expressed on activated cells as a means of making those cells more
susceptible to apoptosis in order to limit the inflammatory
response. Increased CD95 on monocytes from children with
autism may represent an activated subset of monocytes that have
upregulated the surface expression of this apoptosis marker.
Discussion
The current study was designed to search for cellular markers of
autism. Given the genetic heterogeneity of autism [5] and the near
certainty that autism spectrum disorders have many etiologies and
trajectories, it is noteworthy that the current study has identified
several indications of immune differences in children with autism.
In general, we found that the frequencies and phenotypes of whole
blood immune cell subpopulations under non-stimulated condi-
tions were different in children with autism compared with well
matched, typically developing controls. Based on 644 measure-
ments relating cell counts of immune subsets and the abundance of
cellular markers, as determined by the intensity of antibody
staining directed to these markers, nearly a quarter (151) of these
measurements were different between children with autism
compared with controls at the univariate p,0.05 statistical level.
There was additional evidence of differences between higher
functioning autism participants and lower functioning autism
participants with 33 of the measured variables being different
between the autism groups at the p,0.05 level. Notably, the data
highlighted significantly higher absolute numbers of B cells and
NK cells in children with autism compared with controls. In
addition, increased markers of cellular activation, such as CD38
on B cells, and HLA-DR and CD26 on T cell subsets, were
observed on cells from autism participants compared with
controls.
Previous reports have demonstrated differences in lymphocyte
populations in autism, including increased numbers of NK cells
[14] and reduced numbers of T cells [10,19,20,46,47] or altered
activation status of T cell subsets [8,21]. In the current study,
participants were selected in a very narrow age range (4-to-6
years), to coincide with peak symptom presentation and to ensure
a stable diagnosis; the male to female frequency was the same in
each group (29 males to 6 females). Participants in the diagnostic
group had strictly defined autistic disorder and were compared to
a comprehensively evaluated control group of typically developing
children, none of whom were siblings of the autism cases. It is
difficult to make direct comparisons between our study and the
majority of previous studies due to differences in analytical
technique, the age range of the subjects, the diagnostic criteria
used, the lack of confirmation of the absence of ASD or other
neurodevelopmental disorders in the controls and the use of
siblings as controls. In addition, in previous studies there may also
have been unintentional selection bias due to recruitment through
specialist clinics that may have skewed selection of only children
Table 3. Significant measures for study comparisons - counts only.
P value criteria Chance
Autism vs. Typically
developing
HFA vs. Typically
developing
LFA vs. Typically
developing HFA vs LFA
HFA vs. LFA vs. Typically
developing
p,0.001 ,1 5 1 2 0 2
p,0.01 2 23 11 14 2 10
p,0.05 11 43 42 39 4 36
Based on 224 count variables.
doi:10.1371/journal.pone.0019299.t003
Table 4. Significant measures for study comparisons - intensity only.
P value criteria Chance
Autism vs. Typically
developing
HFA vs. Typically
developing
LFA vs. Typically
developing HFA vs LFA
HFA vs. LFA vs. Typically
developing
p,0.001 ,1 16 2 20 1 10
p,0.01 4 54 14 62 5 44
p,0.05 21 108 59 123 29 103
Based on 420 fluorescence intensity variables.
doi:10.1371/journal.pone.0019299.t004
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with regression or children with overt gastrointestinal symptoms.
However, taken together, the current study and existing literature
would strongly support the hypothesis that cellular immune
abnormalities exist in a substantial subset of children with autism.
Findings from our current study describe increases in NK cells
from children with autism compared to typically developing
controls. These data are in line with a previous report of greater
frequencies of NK cells and increased gene expression of NK cell-
related cellular receptors and effector molecules in children with
autism [14]. A number of studies have however, shown decreased
responsiveness of NK cells to in vitro stimulation [14–16]. The
increase in NK cell numbers seen in this study may therefore
reflect a compensatory mechanism to increase cell numbers to
make up for possible deficits in NK cell function. However,
reduced activation after stimulation could also occur if the NK
cells were already maximally stimulated in vivo, a phenomenon
frequently observed in autoimmune diseases. Furthermore, NK
cells have been shown to play a critical role in the initiation of
autoimmune-like responses in diabetes and celiac disease [re-
viewed in 48]. The increased presence of auto-antibodies to brain
and CNS proteins is a common finding in autism and may reflect
an ongoing inflammatory and or autoimmune process in children
with autism that could be initiated by abnormal NK cell activation
[6]. In this case, the expansion of NK cell numbers may result
from heightened immune/autoimmune responses most likely
mediated through the increased production of homeostatic and
growth factors such as cytokines.
The frequency of mature (CD5n) and activated (CD38p) B cells
were also increased in this study and could also contribute to
increased production of auto-antibodies. Cytokines such as IL-6
participate in the activation and differentiation of B cells and their
production of antibodies; previous studies have shown that there
are increased plasma IL-6 levels in children with autism which
could modulate B cell activity [12]. In addition, T cells help B cells
to produce antibodies typically through the production of
cytokines. Recent studies show that in vitro stimulation of T cells
leads to increased production of IL-13 and IL-5 that promote
activation and antibody production from B cells [8,9]. Moreover,
in this study we find that T cells express a profile of cell surface
markers such as HLA-DR and CD26 that are indicative of
activation and are in line with previous reports of altered T cell
activation in children with autism [8,22]. Taken together, our
results suggests that there is an activation of immune responses in
children with autism that leads to increased frequency of NK cells,
and activated B cells and T cells. It is tempting to further suggest
that these cell types may interact in such a way as to break
immunological tolerance to self proteins and to elicit auto-immune
responses leading to the production of auto-antibodies. The
balance between regulatory T cells and TH17 cells are important
in the initiation of autoimmune diseases. In our previous studies,
we did not find a difference in the frequency of circulating FoxP3+
Table 5. Comparison of major blood cell populations between Autism and Typical groups.
Typical Developing controls (N=35) Autism (N=70) P-Values
Cell Population Trend Mean SD Mean SD
WBC q 7524 1783 8220 2238 0.169
Granulocytes - 3441 1474 3582 1519 0.557
Neutrophils - 3398 1490 3401 1435 0.747
T cells - 1834 629 1961 612 0.330
CD4 T cells - 1118 437 1211 459 0.330
CD8 T cells - 664 267 686 249 0.560
B cells q 542 279 661 255 0.003
NK cells q 117 80 161 95 0.011
Monocytes - 446 182 453 188 1
Eosinophils q 286 225 438 515 0.066
Platelets q 1430357 505854 1613025 628482 0.188
N is the number of subjects. Values are absolute cell numbers per microliter. Univariate p-values are shown.
doi:10.1371/journal.pone.0019299.t005
Figure 1. Average B cell counts are higher in the HFA and LFA
groups compared with controls. The absolute count values are
based on 9 separate B cell assays that use CD20 as the B cell identifier.
P-values = * HFA vs. N= 0.011, ** LFA vs. N = 0.009, and A vs. N 0.003.
HFA vs. LFA=not significant (0.7).
doi:10.1371/journal.pone.0019299.g001
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or CD25++ regulatory T cells under resting conditions [8,49];
however, regulatory cell function in children with autism may be
altered as we have shown decreases in TGFb1 levels [50] and IL-
10 production [51,52]. So far, in children with autism aged
between 2 and 5 years of age we have found no differences in IL-
17 plasma levels [53], TH17 cell frequency at baseline levels or
following stimulation, and IL-17 production following stimulation
[49]. Taken together these data do not suggest that there are
differences in TH17 in children with autism of this age range but
they can not rule out earlier alterations in TH17 cell function that
may be linked to causation of autism. Further assessments of TH17
and regulatory T cells and their interactions in autism needs
further investigation.
We, and others, have performed preliminary analyses that
suggest that certain immunological parameters are associated with
specific behavioral symptoms in autism. Impairments in social
behaviors, for example, are associated with decreased levels of
TGFb1 [50], increased IL-1b and IL-13 [12], increased
macrophage inhibitory factor [54], decreased platelet-endothelial
adhesion molecule [55], total IgG [27], increased IgG4 isotype
[26], altered T cell responses [8], chemokine levels [56] and
activated monocyte responses [17]. In addition, parallel proteomic
analysis of sera samples from the same participants in this study
showed increased immune profiles with marked differences in
complement components in children with autism compared with
typical developing controls [13]. The causal link, however,
between these immune factors and behavioral output remains
unexplored. Moreover, no one marker is diagnostic of autism and
the results reported here imply that panels or ‘‘signature’’ profiles
containing multiple markers may associate more specifically with
distinct symptomatology. Further work to determine the potential
use of immune based panels as the basis for defining autism
phenotypes is called for. These studies should include ‘‘at-risk’’
groups where identification of autism before behavioral symptoms
are manifest would be a major advance for the care and
management of such individuals. However, a major challenge in
the identification of reliable early biomarkers is to minimize the
effects of confounding factors such as medication, which may be
more prevalent in the autism group. In this study, we recruited
drug-naı¨ve participants, and carefully screened and selected well-
matched controls. Future studies will need to consider collecting
even more in-depth and extensive demographic information about
all aspects of lifestyle in order to minimize the effects of as yet
unidentified potential confounders.
Currently there is insufficient evidence to refute or confirm the
presence of specific immune dysfunction in autism and it is still
unclear whether immune alterations are reflective of specific
immune dysfunction, or a bystander effect of upstream regulatory
mechanisms, or result from tissue pathology associated with the
disorder. This study does not seek to confirm or address specific
immunological issues in children with autism but rather to
investigate whether immune parameters may be useful as
biological markers in autism. To start to address the complexity
of this symptomatically defined disorder, we need to conduct
studies aimed at identifying clear and consistent differences
between individuals with autism and controls. One potential
limitation of the current study is that it was cross-sectional and that
we only looked at the immune parameters at one time point.
Immune responses are exceedingly dynamic and it is often hard to
achieve a comprehensive assessment of an immune response by
looking at just one point in time. Also, physiological inflammation
may be transient and could be missed if participants are sampled
at one time point only. Larger immunological studies need to be
carried out, where several parameters can be measured and
correlated for the same individual with follow up tests throughout
the progression of the disorder.
A major problem of studies of autism to date has been the
inability of one study to replicate the biological markers found in
another study. This applies to almost any aspect or facet measured
in subjects with autism. As autism is a complex and heterogeneous
Table 6. Comparison of B cell subsets.
Typical Developing controls (N=35) Autism (N=70) P-Values
Cell Population Trend Mean SD Mean SD Univariate
B cells q 542 279 661 255 0.003
CD5n q 268.26 167.45 348.89 139 0.001
CD38p q 394.65 199.91 479.71 210.22 0.008
N is the number of subjects. Values are cell numbers per microliter. Univariate p-values are shown.
doi:10.1371/journal.pone.0019299.t006
Figure 2. Average NK cell counts are higher in the HFA and LFA
groups compared with typically developing controls. The
average is based on 2 separate NK cell assays that use the CD56p
and CD3n as the NK cell identifier. P-values = *HFA vs. N= 0.037, *LFA vs.
N = 0.023, and A vs. N= 0.011. HFA vs. LFA= not significant (0.8).
doi:10.1371/journal.pone.0019299.g002
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disorder that may have multiple causes, pathologies and
trajectories, the assumption that autism is a single disorder, and
that a given finding should extend across all subjects with autism,
may not be tenable. In fact, one of the many difficulties in
understanding autism may be that many different abnormalities
may converge to produce similar behavioral symptoms in autism
subjects. In order to begin to untangle the interaction between
complex genetic and/or environmental factors in autism, it is
essential to identify a reliable biomarker(s) that will help provide
invaluable insight to elucidate mechanisms of action that underlie
the causes of autism. Identifying these biomarkers could help
identify different subgroups within the autism population. If
possible, the discovery of true biomarkers will almost certainly
yield more successful genetic and functional studies and ultimately
will help in the design of efficacious treatments for autism.
A lack of objective, biomedical analytical tools is a serious
limitation to the diagnosis of autism. There are several reasons to
adopt multiplex immunoassays, including those presented in this
study, as a technology to determine possible biomarkers in autism.
‘‘Signature’’ profiles of biomarkers that provide information
regarding possible subclasses within autism and that correlate
with behavioral states of autism would be extremely informative.
An important aspect for future clinical application of such
technology is that the potential biological signatures are suited to
analyzing serial samples in longitudinal studies. The search for the
identification of autism markers in the laboratory is an important
research endeavor, yet the translation of such findings into the
clinic is the real challenge and requires the investigation of much
larger sample cohorts, ideally collected in different clinical centers.
Further studies to examine the clinical power and utility of
putative markers for autism, including those related to the immune
response, are needed to help determine the usefulness in assisting
early diagnosis of autism.
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Table 7. The 20 most different cell surface markers based on fluorescent intensities.
Assay panel
Cell surface
marker Trend Autism (N=70)
Typical Developing
controls (N=35) P-Value % Ratio
Mean SD Mean SD
Intensity Differences .31%
CD16pCD66bpCD52n CD52 q 4453.5 1399 3395.8 1622.2 0.000 131
CD4pnCD14pCD95p CD95 q 3632.8 1629.4 2764.9 705.8 0.002 131
CD3pCD4nHLADRp HLA-DR q 2746 2019.5 2073.8 1281.9 0.020 132
CD4pnCD14pCD25p CD4 q 254.2 189.5 193.6 196 0.040 131
Intensity Differences 25–30%
CD7pCD8pCD26p CD26 q 1149 390.5 887.4 202.4 0.000 129
Neutrophil-CD66b CD66b q 4574.8 1275.6 3531.8 1310.6 0.000 130
CD16pCD66bpCD52p CD66b q 4415 1392.3 3489 1284.5 0.002 127
CD8pnCD57pCD94p CD94 q 1911.4 1016.2 1473.3 780.4 0.040 130
Intensity Differences 21–25%
CCR5nCD8pCD60n CD8 q 2278.5 479.4 1873.8 451.7 0.000 122
CD8pCD20nCD38n CD8 q 2762.6 691 2285.8 612.5 0.001 121
CD3pCD4pHLADRp HLA-DR q 1166.5 626.2 964.7 991 0.001 121
CD8nCD16pCD101p CD101 Q 970.5 439.5 1228 383.2 0.004 79
CD11bpnCD16pnCD32p CD32 Q 745.7 573.1 964.1 685.6 0.030 77
CCR5pCD4pCD60p CD4 q 1594.7 920.9 1282.4 638.7 0.030 124
Intensity Differences 16–20%
CD8pCD45RApCD60p CD8 q 2717.3 462.1 2343.4 463.6 0.000 116
CD8pCD20nCD95n CD8 q 2306 472.2 1981.9 404.1 0.001 116
CD11bpCD16p CD11b q 2865.7 661.6 2390 691 0.001 120
CD14nCD15pCD89p CD15 q 2478.2 619.4 2112.4 722 0.006 117
CD16pnCD18pCD44p CD44 Q 1654.1 740.3 2004 808.5 0.012 83
CCR5pCD8pCD60n CCR5 q 856.6 324.1 739.8 232.6 0.030 116
Abbreviations: p = positive staining, n = negative staining, pn =weak positive staining, N =number. Univariate P value is shown to 3 decimal points only.
Ranking is based on intensity differences of 15% or more between autism and typically developing controls and statistical significance.
doi:10.1371/journal.pone.0019299.t007
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